Clinical Trial

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-08-31 2026-07-14
minor Completion pushed: 2026-06 -> 2026-08-31 2026-07-14
Trial Details
NCT Number NCT04883957
Lead Sponsor BeiGene
Conditions Mature B-cell Malignancies
Enrollment 64 participants
Start Date 2021-07-05
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13